cal33 Search Results


cal33  (DSMZ)
95
DSMZ cal33
Cal33, supplied by DSMZ, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cal33/product/DSMZ
Average 95 stars, based on 1 article reviews
cal33 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
cal-33 tumor cells  (Mediatech)
90
Mediatech cal-33 tumor cells
Cal 33 Tumor Cells, supplied by Mediatech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cal-33 tumor cells/product/Mediatech
Average 90 stars, based on 1 article reviews
cal-33 tumor cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
sh-serpine1-cal27  (SAS institute)
90
SAS institute sh-serpine1-cal27
The hub genes in the intersection based on a Venn analysis
Sh Serpine1 Cal27, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sh-serpine1-cal27/product/SAS institute
Average 90 stars, based on 1 article reviews
sh-serpine1-cal27 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cal33  (IDEXX)
90
IDEXX cal33
The hub genes in the intersection based on a Venn analysis
Cal33, supplied by IDEXX, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cal33/product/IDEXX
Average 90 stars, based on 1 article reviews
cal33 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cal33 cells  (Janvier Labs)
90
Janvier Labs cal33 cells
In vivo monitoring of C29 efficacy by 18 F-FDG PET/CT. (a) . Flow chart of the study. (b) . Representative CT images (left) and 18 F-FDG PET images (right) of tumors from control (left panel) or C29-treated (right panel) mice performed at baseline (T0) and 4 days after treatment (TF). (c) . Evolution of 18 F-FDG tumor uptake in <t>CAL33</t> tumors between TF and T0. Relative changes between TF and T0 in normalized tumor uptake was plotted. **p < 0.01 vs untreated.
Cal33 Cells, supplied by Janvier Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cal33 cells/product/Janvier Labs
Average 90 stars, based on 1 article reviews
cal33 cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cal33  (Bioarray Inc)
90
Bioarray Inc cal33
In vivo monitoring of C29 efficacy by 18 F-FDG PET/CT. (a) . Flow chart of the study. (b) . Representative CT images (left) and 18 F-FDG PET images (right) of tumors from control (left panel) or C29-treated (right panel) mice performed at baseline (T0) and 4 days after treatment (TF). (c) . Evolution of 18 F-FDG tumor uptake in <t>CAL33</t> tumors between TF and T0. Relative changes between TF and T0 in normalized tumor uptake was plotted. **p < 0.01 vs untreated.
Cal33, supplied by Bioarray Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cal33/product/Bioarray Inc
Average 90 stars, based on 1 article reviews
cal33 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cal33  (Eppendorf AG)
90
Eppendorf AG cal33
In vivo monitoring of C29 efficacy by 18 F-FDG PET/CT. (a) . Flow chart of the study. (b) . Representative CT images (left) and 18 F-FDG PET images (right) of tumors from control (left panel) or C29-treated (right panel) mice performed at baseline (T0) and 4 days after treatment (TF). (c) . Evolution of 18 F-FDG tumor uptake in <t>CAL33</t> tumors between TF and T0. Relative changes between TF and T0 in normalized tumor uptake was plotted. **p < 0.01 vs untreated.
Cal33, supplied by Eppendorf AG, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cal33/product/Eppendorf AG
Average 90 stars, based on 1 article reviews
cal33 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cal33  (iCell Bioscience Inc)
90
iCell Bioscience Inc cal33
In vivo monitoring of C29 efficacy by 18 F-FDG PET/CT. (a) . Flow chart of the study. (b) . Representative CT images (left) and 18 F-FDG PET images (right) of tumors from control (left panel) or C29-treated (right panel) mice performed at baseline (T0) and 4 days after treatment (TF). (c) . Evolution of 18 F-FDG tumor uptake in <t>CAL33</t> tumors between TF and T0. Relative changes between TF and T0 in normalized tumor uptake was plotted. **p < 0.01 vs untreated.
Cal33, supplied by iCell Bioscience Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cal33/product/iCell Bioscience Inc
Average 90 stars, based on 1 article reviews
cal33 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cal-33 cell line csc-c0479  (Creative Bioarray Inc)
90
Creative Bioarray Inc cal-33 cell line csc-c0479
In vivo monitoring of C29 efficacy by 18 F-FDG PET/CT. (a) . Flow chart of the study. (b) . Representative CT images (left) and 18 F-FDG PET images (right) of tumors from control (left panel) or C29-treated (right panel) mice performed at baseline (T0) and 4 days after treatment (TF). (c) . Evolution of 18 F-FDG tumor uptake in <t>CAL33</t> tumors between TF and T0. Relative changes between TF and T0 in normalized tumor uptake was plotted. **p < 0.01 vs untreated.
Cal 33 Cell Line Csc C0479, supplied by Creative Bioarray Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cal-33 cell line csc-c0479/product/Creative Bioarray Inc
Average 90 stars, based on 1 article reviews
cal-33 cell line csc-c0479 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
human hnscc cell lines umscc-1, cal33, 1483 and umscc-22a  (Cellgro)
90
Cellgro human hnscc cell lines umscc-1, cal33, 1483 and umscc-22a
In vivo monitoring of C29 efficacy by 18 F-FDG PET/CT. (a) . Flow chart of the study. (b) . Representative CT images (left) and 18 F-FDG PET images (right) of tumors from control (left panel) or C29-treated (right panel) mice performed at baseline (T0) and 4 days after treatment (TF). (c) . Evolution of 18 F-FDG tumor uptake in <t>CAL33</t> tumors between TF and T0. Relative changes between TF and T0 in normalized tumor uptake was plotted. **p < 0.01 vs untreated.
Human Hnscc Cell Lines Umscc 1, Cal33, 1483 And Umscc 22a, supplied by Cellgro, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human hnscc cell lines umscc-1, cal33, 1483 and umscc-22a/product/Cellgro
Average 90 stars, based on 1 article reviews
human hnscc cell lines umscc-1, cal33, 1483 and umscc-22a - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cal33  (JCRB Cell Bank)
90
JCRB Cell Bank cal33
In vivo monitoring of C29 efficacy by 18 F-FDG PET/CT. (a) . Flow chart of the study. (b) . Representative CT images (left) and 18 F-FDG PET images (right) of tumors from control (left panel) or C29-treated (right panel) mice performed at baseline (T0) and 4 days after treatment (TF). (c) . Evolution of 18 F-FDG tumor uptake in <t>CAL33</t> tumors between TF and T0. Relative changes between TF and T0 in normalized tumor uptake was plotted. **p < 0.01 vs untreated.
Cal33, supplied by JCRB Cell Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cal33/product/JCRB Cell Bank
Average 90 stars, based on 1 article reviews
cal33 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cal33-shcontrol cells  (Jackson Laboratory)
90
Jackson Laboratory cal33-shcontrol cells
In vivo monitoring of C29 efficacy by 18 F-FDG PET/CT. (a) . Flow chart of the study. (b) . Representative CT images (left) and 18 F-FDG PET images (right) of tumors from control (left panel) or C29-treated (right panel) mice performed at baseline (T0) and 4 days after treatment (TF). (c) . Evolution of 18 F-FDG tumor uptake in <t>CAL33</t> tumors between TF and T0. Relative changes between TF and T0 in normalized tumor uptake was plotted. **p < 0.01 vs untreated.
Cal33 Shcontrol Cells, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cal33-shcontrol cells/product/Jackson Laboratory
Average 90 stars, based on 1 article reviews
cal33-shcontrol cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


The hub genes in the intersection based on a Venn analysis

Journal: Clinical and Experimental Otorhinolaryngology

Article Title: SERPINE1 as an Independent Prognostic Marker and Therapeutic Target for Nicotine-Related Oral Carcinoma

doi: 10.21053/ceo.2022.01480

Figure Lengend Snippet: The hub genes in the intersection based on a Venn analysis

Article Snippet: The cell proliferation assays showed that the cell viability ( ) and colony formation capability ( ) were significantly weakened in the SERPINE1 -knockdown cells (sh- SERPINE1 -CAL27 and sh- SERPINE1 -SAS) relative to the controls ( P <0.05).

Techniques:

(A) The expression of SERPINE1 in pan-cancer based on The Cancer Genome Atlas (TCGA) database. SERPINE1 expression was significantly higher in head and neck cancer (HNC) tissues than in normal tissues ( P <0.001). (B, C) The survival curves showed that HNC patients with high SERPINE1 expression had a shorter overall survival time than those with low SERPINE1 expression ( P <0.05). (B) TCGA. (C) GSE65858. (D) Multivariate Cox regression analysis with different variables indicated that SERPINE1 was an independent prognostic factor for HNC ( P <0.05). (E) TNMplot presented that high expression of SERPINE1 was associated with metastasis ( P <0.05). (F) The predicted targets of SERPINE1 . The interaction plot showed 57 target genes that may be closely related to SERPINE1 . (G, H) Gene Ontology (GO; G) and Kyoto Encyclopedia of Genes and Genomes (KEGG; H) enrichment analyses of the 57 genes. TPM, transcripts per million; HR, hazard ratio; CI, confidence interval; pT, pathological tumor; pN, pathological N; pTNM, pathological tumor-node-metastasis; TGF, transforming growth factor. * P <0.05; ** P <0.01; *** P <0.001.

Journal: Clinical and Experimental Otorhinolaryngology

Article Title: SERPINE1 as an Independent Prognostic Marker and Therapeutic Target for Nicotine-Related Oral Carcinoma

doi: 10.21053/ceo.2022.01480

Figure Lengend Snippet: (A) The expression of SERPINE1 in pan-cancer based on The Cancer Genome Atlas (TCGA) database. SERPINE1 expression was significantly higher in head and neck cancer (HNC) tissues than in normal tissues ( P <0.001). (B, C) The survival curves showed that HNC patients with high SERPINE1 expression had a shorter overall survival time than those with low SERPINE1 expression ( P <0.05). (B) TCGA. (C) GSE65858. (D) Multivariate Cox regression analysis with different variables indicated that SERPINE1 was an independent prognostic factor for HNC ( P <0.05). (E) TNMplot presented that high expression of SERPINE1 was associated with metastasis ( P <0.05). (F) The predicted targets of SERPINE1 . The interaction plot showed 57 target genes that may be closely related to SERPINE1 . (G, H) Gene Ontology (GO; G) and Kyoto Encyclopedia of Genes and Genomes (KEGG; H) enrichment analyses of the 57 genes. TPM, transcripts per million; HR, hazard ratio; CI, confidence interval; pT, pathological tumor; pN, pathological N; pTNM, pathological tumor-node-metastasis; TGF, transforming growth factor. * P <0.05; ** P <0.01; *** P <0.001.

Article Snippet: The cell proliferation assays showed that the cell viability ( ) and colony formation capability ( ) were significantly weakened in the SERPINE1 -knockdown cells (sh- SERPINE1 -CAL27 and sh- SERPINE1 -SAS) relative to the controls ( P <0.05).

Techniques: Expressing

Associations between SERPINE1 expression and clinicopathological factors in oral cancer (TCGA)

Journal: Clinical and Experimental Otorhinolaryngology

Article Title: SERPINE1 as an Independent Prognostic Marker and Therapeutic Target for Nicotine-Related Oral Carcinoma

doi: 10.21053/ceo.2022.01480

Figure Lengend Snippet: Associations between SERPINE1 expression and clinicopathological factors in oral cancer (TCGA)

Article Snippet: The cell proliferation assays showed that the cell viability ( ) and colony formation capability ( ) were significantly weakened in the SERPINE1 -knockdown cells (sh- SERPINE1 -CAL27 and sh- SERPINE1 -SAS) relative to the controls ( P <0.05).

Techniques: Expressing

(A) The association between SERPINE1 expression and tumor purity, as well as the infiltration levels of several immune cells (TIMER algorithm). (B) Analysis of the relationship between the expression of SERPINE1 and the infiltration levels of 22 types of immune cells by the Cibersort algorithm. The darker color indicates a higher correlation ( * P <0.05). (C) The correlation of SERPINE1 expression with malignant phenotypes in head and neck cancer tissues. Scatter plots showed positive correlations between SERPINE1 expression and malignant phenotypes, such as (C1) metastasis, (C2) hypoxia, (C3) the epithelial-mesenchymal transition, and (C4) angiogenesis. (D) The relationship between SERPINE1 expression and the drug sensitivity of cancer cells. Red represents a positive correlation, while blue stands for a negative correlation. TPM, transcripts per million; TCGA, The Cancer Genome Atlas; HNSC, Head and Neck squamous cell carcinoma; NK, natural killer; EMT, epithelial-mesenchymal transition; GDSC, Genomics of Drug Sensitivity in Cancer; mRNA, messenger RNA; FDR, false discovery rate.

Journal: Clinical and Experimental Otorhinolaryngology

Article Title: SERPINE1 as an Independent Prognostic Marker and Therapeutic Target for Nicotine-Related Oral Carcinoma

doi: 10.21053/ceo.2022.01480

Figure Lengend Snippet: (A) The association between SERPINE1 expression and tumor purity, as well as the infiltration levels of several immune cells (TIMER algorithm). (B) Analysis of the relationship between the expression of SERPINE1 and the infiltration levels of 22 types of immune cells by the Cibersort algorithm. The darker color indicates a higher correlation ( * P <0.05). (C) The correlation of SERPINE1 expression with malignant phenotypes in head and neck cancer tissues. Scatter plots showed positive correlations between SERPINE1 expression and malignant phenotypes, such as (C1) metastasis, (C2) hypoxia, (C3) the epithelial-mesenchymal transition, and (C4) angiogenesis. (D) The relationship between SERPINE1 expression and the drug sensitivity of cancer cells. Red represents a positive correlation, while blue stands for a negative correlation. TPM, transcripts per million; TCGA, The Cancer Genome Atlas; HNSC, Head and Neck squamous cell carcinoma; NK, natural killer; EMT, epithelial-mesenchymal transition; GDSC, Genomics of Drug Sensitivity in Cancer; mRNA, messenger RNA; FDR, false discovery rate.

Article Snippet: The cell proliferation assays showed that the cell viability ( ) and colony formation capability ( ) were significantly weakened in the SERPINE1 -knockdown cells (sh- SERPINE1 -CAL27 and sh- SERPINE1 -SAS) relative to the controls ( P <0.05).

Techniques: Expressing

(A) The messenger RNA (mRNA) expression of SERPINE1 was higher in nicotine-treated oral cells (DOK/NIC) and oral cancer cell lines (Cal27, SAS, HSC-3) than that in DOK cells, respectively. (B) The immunohistochemistry scores of SERPINE1 protein expression in oral cancer tissues were markedly higher than in the normal controls. (C) The expression scores for SERPINE1 protein were higher in cancer samples with lymph node metastasis (LNM) than in those without LNM. (D) The scores of SERPINE1 expression were higher in the samples with high pathological stages than in those with low stages. No associations were presented concerning age (E), sex (F), and Tstage (G). IHC, immunohistochemistry; NS, not significant ( P >0.05). * P <0.05.

Journal: Clinical and Experimental Otorhinolaryngology

Article Title: SERPINE1 as an Independent Prognostic Marker and Therapeutic Target for Nicotine-Related Oral Carcinoma

doi: 10.21053/ceo.2022.01480

Figure Lengend Snippet: (A) The messenger RNA (mRNA) expression of SERPINE1 was higher in nicotine-treated oral cells (DOK/NIC) and oral cancer cell lines (Cal27, SAS, HSC-3) than that in DOK cells, respectively. (B) The immunohistochemistry scores of SERPINE1 protein expression in oral cancer tissues were markedly higher than in the normal controls. (C) The expression scores for SERPINE1 protein were higher in cancer samples with lymph node metastasis (LNM) than in those without LNM. (D) The scores of SERPINE1 expression were higher in the samples with high pathological stages than in those with low stages. No associations were presented concerning age (E), sex (F), and Tstage (G). IHC, immunohistochemistry; NS, not significant ( P >0.05). * P <0.05.

Article Snippet: The cell proliferation assays showed that the cell viability ( ) and colony formation capability ( ) were significantly weakened in the SERPINE1 -knockdown cells (sh- SERPINE1 -CAL27 and sh- SERPINE1 -SAS) relative to the controls ( P <0.05).

Techniques: Expressing, Immunohistochemistry

(A) The mRNA expression of SERPINE1 was significantly downregulated in the SERPINE1 -silenced oral cancer cells (sh- SERPINE1 -Cal27 or sh- SERPINE1 -SAS) compared with that of the control cells (sh-NC-Cal27 and sh-NC-SAS). (B) The trend of SERPINE1 protein expression was in line with that of mRNA expression. (C) The cell proliferation abilities of the SERPINE1 -silenced cancer cells were significantly lower than those of the control cells. (D) The number of colonies formed in the SERPINE1 -silenced cells was significantly lower than that in the control cells. (E) The invasive abilities in the SERPINE1 -silenced cells were significantly inhibited compared with those in the control cells. (F) The administration of Bleomycin or docetaxel resulted in a significant decrease in cell viability in SERPINE1 -silenced cells compared with the control cells. mRNA, messenger RNA; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NC, negative control; OD, optical density. * P <0.05.

Journal: Clinical and Experimental Otorhinolaryngology

Article Title: SERPINE1 as an Independent Prognostic Marker and Therapeutic Target for Nicotine-Related Oral Carcinoma

doi: 10.21053/ceo.2022.01480

Figure Lengend Snippet: (A) The mRNA expression of SERPINE1 was significantly downregulated in the SERPINE1 -silenced oral cancer cells (sh- SERPINE1 -Cal27 or sh- SERPINE1 -SAS) compared with that of the control cells (sh-NC-Cal27 and sh-NC-SAS). (B) The trend of SERPINE1 protein expression was in line with that of mRNA expression. (C) The cell proliferation abilities of the SERPINE1 -silenced cancer cells were significantly lower than those of the control cells. (D) The number of colonies formed in the SERPINE1 -silenced cells was significantly lower than that in the control cells. (E) The invasive abilities in the SERPINE1 -silenced cells were significantly inhibited compared with those in the control cells. (F) The administration of Bleomycin or docetaxel resulted in a significant decrease in cell viability in SERPINE1 -silenced cells compared with the control cells. mRNA, messenger RNA; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NC, negative control; OD, optical density. * P <0.05.

Article Snippet: The cell proliferation assays showed that the cell viability ( ) and colony formation capability ( ) were significantly weakened in the SERPINE1 -knockdown cells (sh- SERPINE1 -CAL27 and sh- SERPINE1 -SAS) relative to the controls ( P <0.05).

Techniques: Expressing, Control, Negative Control

In vivo monitoring of C29 efficacy by 18 F-FDG PET/CT. (a) . Flow chart of the study. (b) . Representative CT images (left) and 18 F-FDG PET images (right) of tumors from control (left panel) or C29-treated (right panel) mice performed at baseline (T0) and 4 days after treatment (TF). (c) . Evolution of 18 F-FDG tumor uptake in CAL33 tumors between TF and T0. Relative changes between TF and T0 in normalized tumor uptake was plotted. **p < 0.01 vs untreated.

Journal: Biochemistry and Biophysics Reports

Article Title: In vivo monitoring of the therapeutic efficacy of a CXCR1/2 inhibitor with 18F-FDG PET/CT imaging in experimental head and neck carcinoma: A feasibility study

doi: 10.1016/j.bbrep.2021.101098

Figure Lengend Snippet: In vivo monitoring of C29 efficacy by 18 F-FDG PET/CT. (a) . Flow chart of the study. (b) . Representative CT images (left) and 18 F-FDG PET images (right) of tumors from control (left panel) or C29-treated (right panel) mice performed at baseline (T0) and 4 days after treatment (TF). (c) . Evolution of 18 F-FDG tumor uptake in CAL33 tumors between TF and T0. Relative changes between TF and T0 in normalized tumor uptake was plotted. **p < 0.01 vs untreated.

Article Snippet: For this study, one million CAL33 cells (RRID:CVCL_1108, human tongue squamous cell carcinoma) were subcutaneously injected in the two flanks of fourteen 6-weeks-old female BALB/cjRj Nude mice (Janvier Labs).

Techniques: In Vivo, Positron Emission Tomography-Computed Tomography, Control

Ki-67 labeling of CAL33 tumor sections . (a) Representative images of Ki67 immunolabeling (green) and Hoechst33342 nuclear DNA counterstaining (blue). Scale bar: 50 μm. (b) Quantification of Ki67-positive cells in CAL33 tumors. **p < 0.01 vs untreated mice.

Journal: Biochemistry and Biophysics Reports

Article Title: In vivo monitoring of the therapeutic efficacy of a CXCR1/2 inhibitor with 18F-FDG PET/CT imaging in experimental head and neck carcinoma: A feasibility study

doi: 10.1016/j.bbrep.2021.101098

Figure Lengend Snippet: Ki-67 labeling of CAL33 tumor sections . (a) Representative images of Ki67 immunolabeling (green) and Hoechst33342 nuclear DNA counterstaining (blue). Scale bar: 50 μm. (b) Quantification of Ki67-positive cells in CAL33 tumors. **p < 0.01 vs untreated mice.

Article Snippet: For this study, one million CAL33 cells (RRID:CVCL_1108, human tongue squamous cell carcinoma) were subcutaneously injected in the two flanks of fourteen 6-weeks-old female BALB/cjRj Nude mice (Janvier Labs).

Techniques: Labeling, Immunolabeling